From: Chemoradiotherapy with concurrent durvalumab for the palliative treatment of oligometastatic oesophageal and gastrooesophageal carcinoma with dysphagia: a single arm phase II clinical trial (PALEO, sponsored by the Australasian Gastro-Intestinal Trials Group)
Haematologic toxicity
Carboplatin
week 2 dose
Paclitaxel
Absolute neutrophil count less than 1.0
Withhold
Platelets less than 75 × 109/L